Stocks / NASDAQ / Grifols, S.A.

Grifols, S.A.

Our Opinion

Grifols, S.A. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.

Supporting Evidence:

The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.

“Grifols is also currently conducting different clinical studies with more than 400 participants in order to obtain data that would allow these kits to be validated using ELISA techniques. Pilot test performed in animal models.” (Page 3) Read the full document

Company Description

Grifols SA is a vertically integrated global producer of plasma derivatives. Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers. The company operates through the following segments: Bioscience, Hospital, Diagnostic and Raw Materials. The Bioscience segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic segment includes the marketing of diagnostic testing equipment, reagents, and other equipment. The Raw Materials segment includes the sale of intermediate biological products and the rendering of manufacturing services to third party companies. Grifols was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain. [Source: MarketWatch]

Company Website: